Последно актуализиране :
02/04/2025
Infostab
Списък с лекарства
Съдържание
Потърсете съвместимост
Таблица за съвместимост на Y-сайта
Библиография
Изследователски екипи
valistab
Плакат
звена
спонсори
Автори
Ръководство за потребителя
Бюлетин
Изследователски екипи - Quality Evaluation Team, Samsung Bioepis Co
Quality Evaluation Team, Samsung Bioepis Co
Incheon
sujin8171.park@samsung.com
To navigate, press the arrow keys.
Библиография
(5)
1
In‑Use Stability of SB12 (Eculizumab, Soliris Biosimilar) Diluted in Saline and Dextrose Infusion Solution after an Extended Storage Period.
Tak M, Jeong H, Yun J, Kim J, Kim S, Lee Y, Park S-J. (sujin8171.park@samsung.com)
Drugs R D -
2023
- ;23,4:363 - 375
2
Physicochemical and Biological Stability Assessment of SB11 (Ranibizumab Biosimilar) Under Ambient and In-Use Storage for Intravitreal Administration.
Kaiser P.K, Yun J, Kim S, Kim J, Park S.J. (sujin8171.park@samsung.com)
Ophtalmol Ther -
2023
- ; 12:985–998.
3
Evaluation of the Physico-Chemical and Biological Stability of SB8 (Aybintio), a Proposed Biosimilar to Bevacizumab, Under Ambient and In-Use Conditions.
Park D, Kim J, Yun J, Park S.J. (sujin8171.park@samsung.com)
Adv Ther -
2020
- ; 37: 4308–4324.
4
Extended Stability of Reconstituted and Diluted SB3 (Trastuzumab Biosimilar) Assessed by Physicochemical and Biological Properties
Yun J, Kim J, Chung J, Hwang S-J, Park S-J. (sujin8171.park@samsung.com)
Adv Ther -
2019
-
5
Evaluation of Physicochemical and Biological Stability of 36-Months-Aged SB5 (Adalimumab Biosimilar) for 4 Weeks at Room Temperature.
Park D, Yun J, Hwang S-J, Park SJ. (sujin8171.park@samsung.com)
Adv Ther -
2019
- 36:442–450
молекули изследвани
(5)
Adalimumab
Bevacizumab
Eculizumab
Ranibizumab
Trastuzumab
Mentions Légales
BESbswy
